Navigation Links
Key patent awarded to Adjuvance co-founders for pioneering method of producing rare vaccine component.
Date:11/14/2012

NEW YORK, Nov. 14, 2012 /PRNewswire-iReach/ -- Adjuvance Technologies, Inc. announced that the United States Patent and Trademark Office has granted Adjuvance co-founders a patent for a pioneering invention which provides a novel synthetic method to produce saponin adjuvants including QS-21, a leading vaccine adjuvant currently used in advanced clinical trials for infectious disease, neurodegenerative disorders and oncology. Despite adjuvants' critical ability to improve the immune response to vaccine antigens, there are very few adjuvants approved for human use in the U.S.

"Before this innovative approach to producing saponin adjuvants, tedious isolation and purification protocols were necessary to obtain these materials. This work will greatly facilitate access to these promising molecules for investigators and vaccine developers" said Jeffrey Gardner, Adjuvance Technologies' CEO and co-founder. As exclusive licensee of the technology, Adjuvance will continue to focus on the commercial development of saponin adjuvants for use in innovative therapeutic and prophylactic human vaccines as well as pandemic preparedness and biodefense efforts.

"At Adjuvance, we believe this technology, which was developed at the Sloan-Kettering Institute of Memorial Sloan-Kettering Cancer Center, represents a fundamental breakthrough in vaccine adjuvant design and manufacturing. This patented technology will be able to expand and accelerate global vaccine programs that require a more secure, consistent source of these promising vaccine adjuvants," noted Mr. Gardner. U.S. Patent No. 8,283,456 was awarded to Drs. David Gin, Philip Livingston, Govind Ragupathi and others for "Triterpene saponins, methods of synthesis, and uses thereof."

About QS-21

QS-21 is a lead investigational adjuvant that has exhibited superior efficacy for a range of vaccine antigens. QS-21 has been widely used in over 100 clinical trials involving approximately 16,000 people. QS-21's ability to augment clinically significant responses to vaccine antigens has convinced GlaxoSmithKline, Johnson & Johnson, CSL and Merck to incorporate QS-21 into their drug development pipelines. In its naturally derived form, QS-21 is a semi-purified plant extract isolated by the harvesting of a rare South American tree, which translates to unique production challenges for vaccine makers. Adjuvance's new patented technology overcomes these production challenges by providing an ecologically sustainable synthetic product that is extremely pure, dependable and scalable.

About Adjuvance Technologies, Inc.

Adjuvance Technologies is a privately owned biopharmaceutical company based in New York. Adjuvance holds an exclusive license to the technology that enables the synthesis of QS-21 as well as an exclusive license to novel analogs with improved tolerability, efficacy and stability. Adjuvance has overcome natural QS-21's production challenges. Adjuvance's patented technology makes it possible to manufacture with consistently high purity and dependability synthetic QS-21 (SAPONEX) as well as an array of novel proprietary TITERQUIL saponin adjuvants on a large scale. More information is available at www.adjuvancetechnologies.com

Media Contact: Jeffrey Gardner Adjuvance Technologies, 3475594258, info@adjuvancetechnologies.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

 


'/>"/>
SOURCE Adjuvance Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Essential Medical Dismisses Patent Case against Masimo and Cercacor
2. Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
3. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
4. U.S. Patent Office Issues Sixth Patent Covering Zero-Footprint Medical Image Viewers to Heart Imaging Technologies, LLC
5. Biodels Intellectual Property Position Strengthened for Ultra-Rapid-Acting Insulin Programs by Notice of Intent to Grant from European Patent Office
6. DURECT Announces Issuance of U.S. Patents Covering ORADUR® Technology
7. Broad Patent Protection Granted for iBio Immunomodulator
8. Bio-AMD, Inc.; Patent Application for Cartridge Test Cap
9. Coloplast Wins Patent Infringement Verdict Against Generic Medical Devices, Inc.
10. ICU Medical, Inc. Plans to "Vigorously Seek to Collect Damages" in wake of Patent Infringement Victory Over RyMed Technologies
11. NeuroSigma Subsidiary Acquires Thin-Film Nitinol Fabrication Patent Portfolio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/8/2017)... DUBLIN, Aug. 8, 2017   ... $3.12 diluted (GAAP) loss per share from continuing operations ... Products revenues increased 16 percent to $110 million ... increased 27 percent to $161 million ... (EPS) from continuing operations increased 8 percent to $0.93 ...
(Date:8/7/2017)... 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation,s largest ... June 30, 2017.  All comparisons, unless otherwise noted, are to ... Second Quarter 2017 Highlights include: ... an increase of 3.5% Total prescriptions dispensed ... of 7.5% versus 7.6% Gross profit ...
(Date:8/3/2017)...  Opioid addiction and other drugs of abuse, blood ... threatening outcomes, were problems taken on directly as laboratory ... support them, met this week. This according to Kalorama ... of abuse, procalcitonin and acute kidney injury were key ... meeting in San Diego, CA. ...
Breaking Medicine Technology:
(Date:8/20/2017)... ... August 20, 2017 , ... State Farm Neighborhood Assist® has named The ... a $25,000 grant. If the initiative wins, Gals Lead – Dream Queen Foundation’s signature ... Tri-County area of St. Mary’s, Calvert and Charles Counties. The program could potentially impact ...
(Date:8/19/2017)... ... August 18, 2017 , ... Paragon and ... database to help the cannabis industry move towards greater legitimacy. By incorporating IOTA’s ... faster technology with lower fees. Paragon will build a fully verifiable database to ...
(Date:8/19/2017)... (PRWEB) , ... August 19, 2017 , ... ... with contemporary illustrations of breastfeeding mothers. These illustrations show the diversity of ... in prints in a wide range of sizes. These illustrations are also available ...
(Date:8/19/2017)... ... August 19, 2017 , ... “Congratulations! It's A Boy! God’s Gift: A Story ... parents and God. “Congratulations! It's A Boy! God’s Gift: A Story of Love” is ... Island, New York. , Published by Christian Faith Publishing, Dale Anthony and Rachael Anthony’s ...
(Date:8/18/2017)... York, New York (PRWEB) , ... ... ... International Courier, LLC, d/b/a Quick International, LLC (“Quick”), a highly specialized asset-light ... announced it has entered into a definitive agreement to purchase Unitrans International ...
Breaking Medicine News(10 mins):